A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

British Journal of Cancer

Volumn 106, Issue 5, 2012, Pages 793-798

  Steele, N ^a   Anthony, A ^b   Saunders, M ^c   Esmarck, B ^d   Ehrnrooth, E ^d   Kristjansen, P E G ^d   Nihlen A ^d   Hansen, L T ^d   Cassidy, J ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b Medical Oncology CRUK Clinical Cancer Centre   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d NOVO NORDISK A S   (Denmark)

Author keywords

cetuximab; colorectal cancer; immunotherapy; rIL 21

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; INTERLEUKIN 2 RECEPTOR ALPHA; RECOMBINANT CYTOKINE; RECOMBINANT HUMAN INTERLEUKIN 21; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CHEILITIS; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONJUNCTIVITIS; CONSTIPATION; COUGHING; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DRY SKIN; DYSPEPSIA; EPISTAXIS; ERYTHEMA; EYE PAIN; FEMALE; FEVER; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; IMMUNOSTIMULATION; LETHARGY; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MOUTH ULCER; MULTICENTER STUDY; NAIL INFECTION; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; NOSE DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN EXFOLIATION; STOMATITIS; T LYMPHOCYTE ACTIVATION; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKINS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84857786741     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.599     Document Type: Article

References (13)

1. Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant AM, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ (2005) A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 93: 1236-1243 (Pubitemid 41679409)
2. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zoubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351: 337-345 (Pubitemid 38944402)
4. Davis ID, Brady B, Kefford RF, Millwrd M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lunsgaard D, Frederiksen KS, Kristjansen PE, McArthur G (2009) Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 15: 2123-2129
5. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, Skak KL, Lundsgaard D, Frederiksen KS, Thygesen P, McArthur GA (2007) An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 13: 3630-3636 (Pubitemid 46955126)
6. Delbaldo C, Pierga JY, Dieras V, Faivre S, Laurence V, Vedovato JC, Bonnay M, Mueser M, Nolting A, Kover A, Raymond E (2005) Pharmacokinetic profile of cetuximab (erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer 41: 1739-1745 (Pubitemid 41132635)
7. Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K (2008) IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 57: 1439-1449
8. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au Hj, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048 (Pubitemid 350106711)
9. Reynolds NA, Wagstaff AJ (2004) Cetuximab in the treatment of metastatic colorectal cancer. Drugs 64: 109-118; discussion 119-121 (Pubitemid 38125631)
10. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson III WE (2007) The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 13: 6419-6428 (Pubitemid 350075032)
11. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF (2008) Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26: 2034-2039
12. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417
13. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, Fujii H (2010) Interleukin-21 can efficiently restore impaired antibodydependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer 102: 520-529